UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000034243
Receipt No. R000038908
Scientific Title A study on the feasibility of the clinical sequence in pediatric hematological malignancies
Date of disclosure of the study information 2018/09/25
Last modified on 2018/09/23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A study on the feasibility of the clinical sequence in pediatric hematological malignancies
Acronym A study on the feasibility of the clinical sequence in pediatric hematological malignancies (JPLSG-CSeq-17)
Scientific Title A study on the feasibility of the clinical sequence in pediatric hematological malignancies
Scientific Title:Acronym A study on the feasibility of the clinical sequence in pediatric hematological malignancies (JPLSG-CSeq-17)
Region
Japan

Condition
Condition Hematological malignancy
Classification by specialty
Hematology and clinical oncology Pediatrics
Classification by malignancy Malignancy
Genomic information YES

Objectives
Narrative objectives1 To assess the feasibility of the clinical sequence in pediatric hematological malignancies by calculating the proportion of cases with potentially interventional findings by the target sequence analysis. The primary endpoint is the proportion of cases in which potentially actionable findings (PAF) are identified by the introducing the clinical sequence.
Basic objectives2 Others
Basic objectives -Others /Proportion of identification of clinically impactful findings (CIF)
/An average number of days to return analysis results to the attending doctor
/Proportion of cases unable to analyze genome and the cause
/Proportion of cases in which germline mutation to be returned was identified
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Proportion of cases in which PAF was identified by introducing the clinical sequence.
Key secondary outcomes /Proportion of identification of CIF
/An average number of days to return analysis results to the attending doctor
/Proportion of cases unable to analyze genome and the cause
/Proportion of cases in which germline mutation to be returned was identified

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit

Not applicable
Age-upper limit
40 years-old >
Gender Male and Female
Key inclusion criteria /Initial ALL (B-others of IR*, HR**, remission induction failure, or T-ALL)
Or recurrent ALL (regardless of the number of relapses)
Or initial AML
Or recurrent AML (regardless of the number of relapses)
/Cases registered in JPLSG-CHM-14
/Cases in which each sample of gene-analyzable tumor and normal cell (including remission phase) is obtained
Tumor: bone marrow fluid (specimen with tumor cell ratio of 20% or more)
Normal cell (including remission phase): peripheral blood in remission, and oral mucosa
/Provided written consent by themselves/the representatives.
*IR: other than HR and NCI-HR
Or PGR, NCI-SR, and M3 on day 15. However, IR rises to HR in case of non-remission at TP1 (day 33).
**HR: with one or more of the following HR factors:
CNS 3 on day 1;
PPR on day 8;
MLL-AF4-positive by day 15;
PGR, NCR-HR at PGR, and MG of day 15;
E2A-HLF gene abnormality by day 29; or
hypodiploid (44 or less) by day 29.
Key exclusion criteria /Cases judged inappropriate for this study by the principal investigator or sub-investigators
/Cases scheduled to participate in other studies for treatment purposes (sponsor-initiated clinical trials, investigator-initiated clinical trials, interventional clinical trials)
Target sample size 25

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Atsushi Manabe
Organization St.Luke's International Hospital
Division name Department of Pediatrics
Zip code
Address 9-1 Akashi-cho, Chuo-ku, Tokyo 104-8560, Japan
TEL 03-3541-5151
Email manabe-luke@umin.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Shinsuke Hirabayashi
Organization St.Luke's International Hospital
Division name Department of Pediatrics
Zip code
Address 9-1 Akashi-cho, Chuo-ku, Tokyo 104-8560, Japan
TEL 03-3541-5151
Homepage URL
Email hirabayashi-slh@umin.ac.jp

Sponsor
Institute Japan Children's Cancer Group
Institute
Department

Funding Source
Organization Japan Agency for Medical Research and Development
Organization
Division
Category of Funding Organization Government offices of other countries
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2018 Year 09 Month 25 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2018 Year 08 Month 17 Day
Date of IRB
Anticipated trial start date
2018 Year 09 Month 25 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information Exploratory endpoint:
proportion of medical treatment conducted based on PAF after 6 months (180 days)

Management information
Registered date
2018 Year 09 Month 23 Day
Last modified on
2018 Year 09 Month 23 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038908

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.